Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes | Zendy

William B. White | Zendy; Christopher P. Can | Zendy; Simon Heller | Zendy; Steven E. Nissen | Zendy; Richard M. Bergenstal | Zendy; George L. Bakris | Zendy; Alfonso T. Perez | Zendy; P. Fleck | Zendy; Cyrus R. Mehta | Zendy; Stuart Kupfer | Zendy; Craig Wilson | Zendy; William C. Cushman | Zendy; Faı̈ez Zannad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Author(s) -

William B. White,

Christopher P. Can,

Simon Heller,

Steven E. Nissen,

Richard M. Bergenstal,

George L. Bakris,

Alfonso T. Perez,

P. Fleck,

Cyrus R. Mehta,

Stuart Kupfer,

Craig Wilson,

William C. Cushman,

Faı̈ez Zannad

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1305889

Subject(s) - alogliptin , medicine , acute coronary syndrome , type 2 diabetes , hazard ratio , myocardial infarction , placebo , clinical endpoint , diabetes mellitus , unstable angina , dipeptidyl peptidase 4 , cardiology , confidence interval , randomized controlled trial , endocrinology , alternative medicine , pathology

To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research